Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
Health Services Research in Oncology: Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Therapy in Real-World Practice
Real World Evidence (RWE) complements the data of randomised clinical trials, that are based on selected, homogeneous patient collectives and a limited study duration, with long-term data from clinical practice. As there has been no evaluation of immunotherapy in everyday care in Austria to date, a retrospective pilot study was conducted in six Austrian hospitals on the efficacy and safety of anti-PD-1/PDL1 monotherapy in patients with NSCLC using routine data.
Non-interventional studies (NIS) are observational studies that evaluate medicinal products and medical devices in routine care after market authorization in their approved indications. For some years now, there has been a critical discussion about their role, whether they are a valuable source of knowledge or a marketing instrument. In Austria, NIS are not subject to approval, but they are subject to notification. The NIS must be registered in a study database (register), in which some (but not all) information is also made publicly accessible. This systematic analysis addresses the questions of how many non-interventional studies are being conducted in Austria, who is responsible for them and what the knowledge interest of the registered NIS is.
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
We are pleased to introduce our three new HSO Fact Sheets.
Fact Sheet No. 57 (July 2021)
Idecabtagene vicleucel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM)
(Good) practice organizational models using real-world evidence for public funding of high prized therapies
The growing market entry of high-cost medicines threatens the financial sustainability of healthcare systems. Limited data available on the benefit of therapies at the time of approval poses a challenge for payers. Outcome-based Managed-entry agreements (OBMEAs) present a reimbursement tool for payers to fund therapies and enable patient access - under conditions. The study aimed to design a generic organizational model for OBMEAs for highly-priced therapies, providing conditional funding while simultaneously generating publicly accessible data on the real-world evidence of treatment effects.
We are pleased to introduce our new reports.
Decision Support Documents 2021:
- DSD 124: Percutaneous left ventricular assist devices: micro-axial flow pumps: https://eprints.aihta.at/1323
- DSD 125: Liposuction for surgical therapy of lipoedema: https://eprints.aihta.at/1324
- DSD 126: Triphasic biomaterial for augmentation of the osteoporotic femoral neck: https://eprints.aihta.at/1325
- DSD 127: Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD): https://eprints.aihta.at/1326
- DSD 128: Allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses: https://eprints.aihta.at/1327
- DSD 129: Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia: https://eprints.aihta.at/1328
- DSD 87/1: Implantation of Bulking Agents for Faecal Incontinence (1st Update): https://eprints.aihta.at/1322
Due to the expected increase in long COVID cases, social consequences have to be considered in addition to the impairments in daily life for the affected persons and their families. For this reason, an overview of the epidemiology of long COVID, possible risk factors, as well as of the consequences on everyday life, was given in the present review within the cooperation with the Belgian HTA institute, KCE.
We are pleased to introduce our four new HSO Fact Sheets.
Fact Sheet No. 51 (Mai 2021)
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer
Fact Sheet No. 54 (Mai 2021)
Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapyfor the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus